H
Holger Cario
Researcher at University of Ulm
Publications - 86
Citations - 2645
Holger Cario is an academic researcher from University of Ulm. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 72 publications receiving 2301 citations. Previous affiliations of Holger Cario include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.
Amy V. Jones,Andrew Chase,Richard T. Silver,David Oscier,Katerina Zoi,Y. Lynn Wang,Holger Cario,Heike L. Pahl,Andrew Collins,Andreas Reiter,Francis H. Grand,Nicholas C.P. Cross +11 more
TL;DR: It is reported here that JAK2V617F-associated disease is strongly associated with a specific constitutional Jak2 haplotype, designated 46/1, in all three disease entities compared to healthy controls and provides a model whereby a constitutional genetic factor is associated with an increased risk of acquiring a specific somatic mutation.
Journal ArticleDOI
Factors influencing success of clinical genome sequencing across a broad spectrum of disorders
Jenny C. Taylor,Jenny C. Taylor,Hilary C. Martin,Stefano Lise,John Broxholme,Jean-Baptiste Cazier,Andrew J. Rimmer,Alexander Kanapin,Gerton Lunter,Simon Fiddy,Chris Allan,A. Radu Aricescu,Moustafa Attar,Christian Babbs,Jennifer Becq,David Beeson,Celeste Bento,P Bignell,Edward Blair,Veronica J. Buckle,Katherine R. Bull,Katherine R. Bull,Ondrej Cais,Holger Cario,Helen Chapel,Richard R. Copley,Richard R. Copley,Richard J. Cornall,Jude Craft,Jude Craft,Karin Dahan,Emma E. Davenport,Calliope A. Dendrou,Olivier Devuyst,Aimee L. Fenwick,Jonathan Flint,Lars Fugger,Rodney D. Gilbert,Anne Goriely,Angie Green,Ingo H. Greger,Russell J. Grocock,Anja V. Gruszczyk,Robert W. Hastings,Edouard Hatton,Doug Higgs,Adrian V. S. Hill,Adrian V. S. Hill,Christopher Holmes,Christopher Holmes,Malcolm F. Howard,Malcolm F. Howard,Linda Hughes,Peter Humburg,David W. Johnson,Fredrik Karpe,Zoya Kingsbury,Usha Kini,Julian C. Knight,Jon P. Krohn,Sarah Lamble,Craig B. Langman,Lorne Lonie,Joshua Luck,Davis J. McCarthy,Simon J. McGowan,Mary Frances McMullin,Kerry A. Miller,Lisa Murray,Andrea H. Németh,M. Andrew Nesbit,David J. Nutt,Elizabeth Ormondroyd,Annette Bang Oturai,Alistair T. Pagnamenta,Alistair T. Pagnamenta,Smita Y. Patel,Melanie J. Percy,Nayia Petousi,Paolo Piazza,Sian E. Piret,Guadalupe Polanco-Echeverry,Niko Popitsch,Niko Popitsch,Fiona Powrie,Christopher W. Pugh,Lynn Quek,Peter A. Robbins,Kathryn J. H. Robson,Alexandra Russo,Natasha Sahgal,Pauline A. van Schouwenburg,Anna Schuh,Anna Schuh,Earl D. Silverman,Alison Simmons,Per Soelberg Sørensen,Elizabeth Sweeney,John Taylor,John Taylor,Rajesh V. Thakker,Ian Tomlinson,Ian Tomlinson,Amy Trebes,Stephen R.F. Twigg,Holm H. Uhlig,Paresh Vyas,Timothy J. Vyse,Steven A. Wall,Hugh Watkins,Michael P. Whyte,Lorna Witty,Ben Wright,Christopher Yau,David Buck,Sean Humphray,Peter J. Ratcliffe,John I. Bell,Andrew O.M. Wilkie,David Bentley,Peter Donnelly,Peter Donnelly,Gilean McVean +122 more
TL;DR: It is found that jointly calling variants across samples, filtering against both local and external databases, deploying multiple annotation tools and using familial transmission above biological plausibility contributed to accuracy.
Journal ArticleDOI
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study
John B. Porter,Renzo Galanello,Giuseppe Saglio,Ellis J. Neufeld,Elliott Vichinsky,Maria Domenica Cappellini,Nancy F. Olivieri,Antonio Piga,Melody J. Cunningham,Denis Soulières,Norbert Gattermann,Gilbert Tchernia,Johan Maertens,Patricia J. Giardina,Janet L. Kwiatkowski,Giovanni Quarta,Michael Jeng,Gian Luca Forni,Michael Stadler,Holger Cario,Louise Debusscher,Matteo G. Della Porta,Mario Cazzola,Peter L. Greenberg,Giuliana Alimena,B. Rabault,Insa Gathmann,John Ford,Daniele Alberti,Christian Rose +29 more
TL;DR: This 1‐yr prospective phase II trial evaluated the efficacy of deferasirox in regularly transfused patients aged 3–81’yrs with myelodysplastic syndromes and other rare anaemias.
Journal ArticleDOI
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia
Maria Domenica Cappellini,Mohamed Bejaoui,Leyla Agaoglu,John B. Porter,Thomas D. Coates,Michael Jeng,Maria Eliana Lai,Antonio Mangiagli,Gabriele Strauss,Robert Girot,Nora Watman,Alina Ferster,Sandra Loggetto,Sharon Abish,Holger Cario,Nicolaos Zoumbos,Elliott Vichinsky,Herbert Opitz,C. Ressayre-Djaffer,Linda Abetz,Diana Rofail,Jean Francois Baladi +21 more
TL;DR: The results suggest that deferasirox had a positive impact on patients' daily lives, and patient-reported satisfaction and convenience were significantly higher for the once-daily, oral ICT defer asirox than for DFO infusions.
Journal ArticleDOI
Insulin sensitivity and β-cell secretion in thalassaemia major with secondary haemochromatosis: assessment by oral glucose tolerance test
TL;DR: Insulin resistance is of central importance for the development of diabetes mellitus in patients with secondary haemochromatosis and an additional early defect in β-cell secretion cannot be excluded.